Items tagged with Drug-resistant TB
TB Alliance announces partnership with Hongqi Pharma to commercialize new therapy for highly drug-resistant forms of TB in China (post)
NEW YORK (January 16, 2020)—Non-profit drug developer TB Alliance has granted Shenyang Hongqi Pharmaceuticals Co., Ltd. (“Hongqi Pharma”), a wholly-owned subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”, stock code: 600196.SH; 02196.HK) a license to market the anti-TB medicine pretomanid as part of the three-drug “BPaL” regimen. Hongqi has agreed to commercialize the anti-tuberculosis (TB) medicine in the People’s Republic of China.
“Lethal” mutation makes TB bacteria resistant to antibiotic (post)
Antibiotic-resistant tuberculosis is a common and serious problem globally. In a new article, researchers from Uppsala University describe how tuberculosis bacteria that carries a mutation that in theory should kill them manages to stay alive. The researchers discovered that the same trick that kept the bacteria alive also made them resistant to a very important type of antibiotic.
WHO FAQs on key changes to the treatment of drug-resistant TB (post)
The World Health Organization (WHO) Global TB Program, in close collaboration with the Global Fund to Fight AIDS, Tuberculosis and Malaria, the United States Agency for International Development (USAID) and the Global Drug Facility of the Stop TB Partnership have updated the Frequently Asked Questions (FAQs) document on WHO’s Rapid Communication: Key changes to the treatment of drug-resistant tuberculosis.
Stop TB Partnership’s Global Drug Facility Pediatric DR-TB Initiative short film (post)
The Stop TB Partnership’s Global Drug Facility (GDF) announced the submission of a short film about the Pediatric Drug-Resistant TB (DR-TB) Initiative into the Webby Awards.
The Union announces results for the shortened DR-TB treatment regimen (post)
Union Study shows long-term effectiveness for shortened DR-TB treatment regimen up to 24 months after treatment completion
RESIST-TB newsletter (post)
New articles highlight emergence of resistance to bedaquiline and underline the need for improved susceptibility testing.
Normal dose moxifloxacin maintained effectiveness in rifampin-resistant TB (post)
A short, 9-month regimen of normal-dose moxifloxacin maintained good effectiveness up to 24 months after the cessation of therapy in patients with rifampicin-resistant tuberculosis (RR-TB), according to the results of an observational cohort study published in EClinicalMedicine.
TB drug delamanid fast drying out, India yet to receive new stocks from Japan (post)
Indian Government is now looking to buy delamanid for the first time from Otsuka.
RESIST-TB webinar: NiX-TB regimen for XDR-TB (post)
RESIST-TB will host a webinar on 26 March 2020 to discuss the recently published work on the NiX-TB trial, which focuses on treatment of extensively drug-resistant TB (XDR-TB).
MSF technical briefs (post)
Médecins Sans Frontières (MSF) updated two of its technical briefs, A rapid TB test for people living with HIV and Making the switch.
Page 63 of 117 · Total posts: 0
←First 62 63 64 Last→